Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5 MONTREAL, May 21, 2020 – Alethia Biotherapeutics announced today that the U.S. Food and Drug Administration has cleared its…